As­traZeneca de­tails ex­pan­sive com­bo strat­e­gy for new oral GLP-1 as ex­ecs wa­ger obe­si­ty mar­ket is ‘here to stay’

By ac­quir­ing Ec­co­gene’s GLP-1, As­traZeneca is bet­ting not just on the long-term po­ten­tial of the obe­si­ty drug mar­ket, but the val­ue of com­bin­ing the weight …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER